These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 20228585)

  • 21. Relationship between five-year histological outcome and serial changes in serum alanine aminotransferase in patients with biochemical and virological relapse after interferon treatment for chronic hepatitis C.
    Kobayashi M; Ikeda K; Akuta N; Someya T; Suzuki F; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Chayama K; Kumada H
    Intervirology; 2000; 43(3):174-9. PubMed ID: 11044811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy.
    Van Thiel DH; Caraceni P; Molloy PJ; Hassanein T; Kania RJ; Gurakar A; Friedlander L
    J Hepatol; 1995 Nov; 23(5):503-8. PubMed ID: 8583136
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
    El Raziky M; Attia D; El Akel W; Shaker O; Khatab H; Abdo S; Elsharkawy A; Esmat G
    Arab J Gastroenterol; 2013 Sep; 14(3):94-8. PubMed ID: 24206736
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels.
    Chen J; Xu CR; Xi M; Hu WW; Tang ZH; Zang GQ
    J Viral Hepat; 2017 Jul; 24(7):573-579. PubMed ID: 28107601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Relation of ALT and AST levels to the histopathological changes in liver biopsies of patients with chronic hepatitis C genotype 4.
    Khattab H; Fouad A; Hamza M; Mohey MA; El-Akel W; Ghoneim H; Abul-Fotouh A; Esmat G
    Arab J Gastroenterol; 2015 Jun; 16(2):50-3. PubMed ID: 26184441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels.
    Hu KQ; Schiff ER; Kowdley KV; Min AD; Shiffman ML; Lee WM; Goodman ZD; Dau LO; Peschell KJ; Fagan EA; Flaherty JF
    J Clin Gastroenterol; 2010 Aug; 44(7):510-6. PubMed ID: 20179614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.
    Alsaran K; Sabry A; Molhem A
    Ren Fail; 2013; 35(10):1305-9. PubMed ID: 24059964
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
    Kronenberger B; Herrmann E; Micol F; von Wagner M; Zeuzem S
    Hepatology; 2004 Dec; 40(6):1442-9. PubMed ID: 15565603
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease progression in chronic hepatitis C patients with normal alanine aminotransferase levels.
    Sinn DH; Gwak GY; Shin JU; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
    World J Gastroenterol; 2013; 19(14):2256-61. PubMed ID: 23599653
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of response to combined interferon alpha-2b and ribavirin therapy in patients of chronic hepatitis c with serum alanine aminotransferase levels and severity of the disease on liver biopsy.
    Nadeem A; Hussain MM; Aslam M; Hussain T; Butt IF; Ali Khan S; Asad A
    J Ayub Med Coll Abbottabad; 2009; 21(2):103-6. PubMed ID: 20524482
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A large-scale, multicentre, double-blind trial of ursodeoxycholic acid in patients with chronic hepatitis C.
    Omata M; Yoshida H; Toyota J; Tomita E; Nishiguchi S; Hayashi N; Iino S; Makino I; Okita K; Toda G; Tanikawa K; Kumada H;
    Gut; 2007 Dec; 56(12):1747-53. PubMed ID: 17573387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of pegylated interferon alfa-2a or alfa-2b in combination with ribavirin in the treatment of chronic hepatitis caused by hepatitis C virus genotype 1b.
    Mach TH; Cieśla A; Warunek W; Janas-Skulina U; Cibor D; Owczarek D; Ciećko-Michalska I
    Pol Arch Med Wewn; 2011 Dec; 121(12):434-9. PubMed ID: 22157768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of pegylated interferon and ribavirin on morbidity and mortality in patients with chronic hepatitis C and normal aminotransferases in France.
    Deuffic-Burban S; Babany G; Lonjon-Domanec I; Deltenre P; Canva-Delcambre V; Dharancy S; Louvet A; Roudot-Thoraval F; Mathurin P
    Hepatology; 2009 Nov; 50(5):1351-9. PubMed ID: 19676130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
    Arora S; O'Brien C; Zeuzem S; Shiffman ML; Diago M; Tran A; Pockros PJ; Reindollar RW; Gane E; Patel K; Wintfeld N; Green J
    J Gastroenterol Hepatol; 2006 Feb; 21(2):406-12. PubMed ID: 16509866
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
    Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
    Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C].
    Wang M; Zheng W; Zhang H; Li Z; Jiang D; Liu Y; Zhou R; Li XG; Zhang Y; Zhang Z; Wu S; Zhang Y; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2014 Apr; 22(4):255-9. PubMed ID: 25173222
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum alanine aminotransferase level and response to interferon-ribavirin combination therapy in patients with chronic hepatitis C.
    Sarwar S; Butt AK; Khan AA; Alam A; Ahmad I; Dilshad A
    J Coll Physicians Surg Pak; 2006 Jul; 16(7):460-3. PubMed ID: 16827956
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized controlled trial of sequential pegylated interferon-α and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B.
    Piccolo P; Lenci I; di Paolo D; Demelia L; Sorbello O; Nosotti L; Angelico M
    Antivir Ther; 2013; 18(1):57-64. PubMed ID: 22872648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating intercellular adhesion molecule-1 in chronic hepatitis C patients with normal or elevated aminotransferase before and after alpha-interferon treatment.
    Montalto G; Giannitrapani L; Soresi M; Florena A; Di Martino D; Franco V; Carroccio A; Cervello M
    Intervirology; 2003; 46(1):35-42. PubMed ID: 12566697
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.